Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P354: Refinement and confirmation of psychometric properties of the Inflammatory Bowel Disease Distress Scale (IBD-DS): A new tool to measure disease-specific distressECCO '18 Vienna
Year: 2018
Authors:

L. Dibley1,2*, W. Czuber-Dochan3, S. Woodward3, T. Wade3, P. Bassett4, J. Sturt3, C. Norton3, The IBD-DS Patient and Public Involvement Team3

1University of Greenwich, Faculty of Education and Health, London, UK, 2Bart's Health NHS Trust, Academic Research Centre, London, UK, 3King's College London, Florence Nightingale School of Nursing and Midwifery, London, UK, 4Stats Consultancy, Amersham, UK

P355: Prevalence, clinical characteristics and outcomes of CMV colitis in a cohort of 95 patients with ulcerative colitis: A 7-year retrospective analysisECCO '18 Vienna
Year: 2018
Authors:

J. Carvão1*, J. Alves2, V. Magno Pereira1, C. Sousa Andrade1, H. Morna1, G. Andrade2, L. Jasmins1

1Hospital Central do Funchal, Gastroenterology, Funchal, Portugal, 2Hospital Central do Funchal, Clinical Pathology, Funchal, Portugal

P356: The role of endoscopic activity in the coagulation profile of clinical remission Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Andrade*, M. Azevedo, A. Carlos, C. Hashimoto, A. Sipahi, A. Damião, E. D´Amico, A. Leite

Faculdade de Medicina da USP, Gastroenterology, São Paulo, Brazil

P357: Healthcare and medication utilisation in Singapore adult inflammatory bowel disease patients receiving immunomodulators and biologicsECCO '18 Vienna
Year: 2018
Authors:

R.E.L. Gan1,2,3, C.K.Y. Ng1, W.C. Ong1, W.P.W. Chan2,3, B.J. Schwender2,3, S.C. Kong2,3, H.H. Shim2,3, K.L. Ling2,3, S.W. Chuah2,3, T.G. Lim1,3*

1Singapore General Hospital, Pharmacy, Singapore, Singapore, 2Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore, 3Duke-NUS Medical School, Singapore, Singapore

P358: Factors associated with disability in inflammatory bowel disease (IBD): A cross-sectional study in outpatientsECCO '18 Vienna
Year: 2018
Authors:

J.M. Costa1*, D. Matos2, R. Costa1, B. Arroja1, R. Gonçalves1, J.B. Soares1

1Hospital de Braga, Gastroenterology, Braga, Portugal, 2School of Health Sciences, University of Minho, Braga, Portugal

P359: A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administrationECCO '18 Vienna
Year: 2018
Authors:

A. Rowley1*, M. Taylor1, A. Duggal1, M. Foster1, S. Sirohi1, Y. Solanke1, C. Walshe1, M. Fyfe1, S. Webber1, S. Travis2

1TopiVert Pharma Ltd., London, UK, 2Oxford University Hospitals Trust, Translational Gastroenterology Unit, Oxford, UK

P360: TrueColours ulcerative colitis (TCUC): Will patients with UC complete digital questionnaires in real-time?ECCO '18 Vienna
Year: 2018
Authors:

A. Walsh1*, M. Peters2, C. Hinds3, A. Kormilitzin4, V. Sexton5, P. Seeva1, O. Brain1, S. Keshav1, H. Uhlig1, A. Simmons6, J. Geddes5, G. Goodwin5, G. Collins7, S. Travis1

1John Radcliffe Hospital, Translational Gastroenterology Unit, Oxford, UK, 2University of Oxford, Nuffield Department of Population Health, Oxford, UK, 3Big Data Institute, Oxford, UK, 4Mathematical Institute, Oxford, UK, 5University of Oxford, Psychiatry Department, Oxford, UK, 6Weatherall Institute of Molecular Medicine, Oxford, UK, 7University of Oxford, Centre for Statistics in Medicine, Oxford, UK

P361: Patterns of use and durability of initial and sequential biological agents in a large Paediatric inflammatory bowel disease observational cohortECCO '18 Vienna
Year: 2018
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

1MassGeneral Hospital for Children, Pediatric Gastroenterology, Boston, USA, 2Harvard Medical School, Boston, USA, 3Cincinnati Children's Hospital, Cincinnati, USA, 4Children’s Mercy Hospital, Kansas City, USA, 5University of Texas-Southwestern/Children's Medical Center, Dallas, USA, 6The Children’s Hospital at Montefiore, Bronx, USA, 7Mayo Clinic-Children’s Center, Rochester, USA, 8Takeda Pharmaceuticals USA, Deerfield, USA, 9University of Vermont College of Medicine, Burlington, USA

P362: Six-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in inflammatory bowel disease patientsECCO '18 Vienna
Year: 2018
Authors:

C. Cassieri1*, R. Pica1, E.V. Avallone1, G. Brandimarte2, M. Zippi1, P. Crispino1, D. De Nitto1, P.G. Lecca2, P. Vernia1, P. Paoluzi1, E.S. Corazziari1

1Sapienza University, Department of Internal Medicine and Medical Specialties, Rome, Italy, Rome, Italy, 2Cristo Re, Hospital, Internal Medicine, “Cristo Re” Hospital, Rome, Italy, Rome, Italy

P363: Discontinuation of 5-aminosalicylates after starting biologic therapy in patients with ulcerative colitis is not associated with adverse outcomesECCO '18 Vienna
Year: 2018
Authors:

B. Limketkai1*, R. Ungaro2, T. Jess3, K. Allin3, M. Agrawal4, T. Ullman2, J.-F. Colombel2

1Stanford University School of Medicine, Gastroenterology and Hepatology, Stanford, California, USA, 2Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, New York, USA, 3Frederiksberg Hospital, Clinical Epidemiology, Frederiksberg, Denmark, 4Montefiore Medical Center, Gastroenterology, Bronx, USA

P364: Stopping azathioprine in monotherapy after very prolonged remission in inflammatory bowel disease patients: Novel relapse risk factorsECCO '18 Vienna
Year: 2018
Authors:

M. Iborra1*, J. Herreras2, M. Boscá-Watts3, X. Cortés4, G. Trejo3, B. Beltran1, E. Cerrillo1, M. Minguez3, P. Nos1

1La Fe University and Polytechnic Hospital and CIBER-EHD, Department of Gastroenterology, Valencia, Spain, 2La Fe University and Polytechnic hospital of Valencia, Department of Gastroenterology and Hepatology, Valencia, Spain, 3University Clinic Hospital of Valencia, Department of Gastroenterology and Hepatology, Valencia, Spain, 4Hospital de Sagunto (Sagunto), Department of Gastroenterology, Valencia, Spain

P365: Biological interventions for induction and maintenance of mucosal healing in Crohn’s disease: A Cochrane systematic reviewECCO '18 Vienna
Year: 2018
Authors:

A. Ricciuto1*, P. Church1, M.J. Stewart2, H.H. Shim2, M. Storr3,4, R. Panaccione2, A. Griffiths1, C. Seow2

1Hospital for Sick Children, University of Toronto, Toronto, Canada, 2University of Calgary, Medicine, Calgary, Canada, 3Ludwig-Maximilians-University Munich, Munich, Germany, 4Center of Endoscopy, Starnberg, Germany

P366: Long-term evolution of gastrointestinal immune-related adverse events (GI-IrAE) induced by immune checkpoint inhibitors (ICI)ECCO '18 Vienna
Year: 2018
Authors:

A. de Malet1*, G. Antoni2, E. Soularue1, M. Collins1, L. Marthey1, T. Vaysse1, C. Mateus3, C. Robert3, F. Carbonnel1

1Bicêtre Hospital - APHP, Gastro-enterology, Kremlin-Bicêtre, France, 2University Hospital Paul Brousse, Liver and biliary-tract disease center, Villejuif, France, 3Universite Paris Sud, Institut Gustave Roussy, Centre for Research in Epidemiology and Population Health / INSERM, UMRS 1018, Team 9, Villejuif, France

P367: Vedolizumab and early postoperative complications in non-intestinal surgery: A case-matched analysisECCO '18 Vienna
Year: 2018
Authors:

P.G. Kotze1*, N. Mckenna2, C. Ma1, A. Almutairdi1, L. Raffals3, E.V. Loftus Jr.3, R. Panaccione1, A. Lightner2

1University of Calgary, IBD Unit, Division of Gastroenterology and Hepatology, Calgary, Canada, 2Mayo Clinic Rochester, Division of Colorectal Surgery, Rochester, USA, 3Mayo Clinic Rochester, Division of Gastroenterology and Hepatology, Rochester, USA

P368: Persistence of biologic therapy and mapping of sequential biologic use: Results of a single centre cohort with 841 patients treated over 18 yearsECCO '18 Vienna
Year: 2018
Authors:

P. Jenkinson*, N. Plevris, C.S. Chuah, M. Lyons, G. Jones, R. Hall, I. Arnott, C. Lees

NHS Lothian, Gastroenterology, Edinburgh, UK

P369: Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with ulcerative colitis: A multicentre studyECCO '18 Vienna
Year: 2018
Authors:

A. Streichenberger1*, B. Pariente2, A. Bozon3, N. Arab4, A. Amiot5, L. Vuitton6, M. Tilmant7, M. Nachury8, R. Altwegg3, T. Delasalle4, C. Gagnière5, B. Grégoire6, M. Fumery7, P. Wils2, G. Pineton de Chambrun3, X. Hébuterne4, B. Pereira9, G. Bommelaer1,10, A. Buisson1,10

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2University Hospital, Gastroenterology Department, Lille, France, 3CHU de Montpellier, Department of Gastroenterology, Montpellier, France, 4Archet 2 University Hospital, Department of Gastroenterology, Nice, France, 5Hospital Henri-Mondor, Department of Gastroenterology, Creteil, France, 6University Hospital of Besançon, Gastroenterology, Besançon, France, 7University Hospital, Gastroenterology Department, Amiens, France, 8University Hospital of Lille, Gastroenterology, Lille, France, 9University Hospital, Biostatistics Unit, DRCI, Clermont-Ferrand, France, 10UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the Host, Clermont-Ferrand, France

P370: Endosponge-assisted early surgical closure of ileal pouch-anal anastomotic leakage improves long-term outcomesECCO '18 Vienna
Year: 2018
Authors:

K.A. Wasmann1*, M.A. Reijntjes1, M.E. Stellingwerf1, C.I. Ponsioen2, C.J. Buskens1, P.J. Tanis1, W.A. Bemelman1

1Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands, 2Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands

P371: Vedolizumab is associated with changes in innate rather than T-cell immunity in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Zeissig1,2*, E. Rosati3, C.M. Dowds3,4, K. Aden2,3, J. Bethge2, B. Schulte2, W.H. Pan3, M. Falk-Paulsen3, C. Conrad2, D. Schuldt2, A. Sinha3, S. Nikolaus2, A. Arlt2, D. Kabelitz4, M. Ellrichmann2, P. Rosenstiel3, A. Franke3, S. Schreiber2,3

1University Medical Center Dresden, Department of Medicine I, Dresden, Germany, 2University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany, 3University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology, Kiel, Germany, 4Christian-Albrechts-Universität zu Kiel, Institute of Immunology, Kiel, Germany

P372: A pilot study: A psychological support service for patients with inflammatory bowel disease (PSSPIBD)ECCO '18 Vienna
Year: 2018
Authors:

R. McGeer1*, A. Ascott1, J. Eccles2, M. Smith1, L. Page2, E. Hills1, A. St-clair Jones1, J. Gregory2

1Brighton and Sussex University Hospitals NHS Trust, UK, Gastroenterology, Brighton and Hove, UK, 2Sussex Partnership NHS Foundation Trust, UK, Liason Psychiatry, Brighton and Hove, UK

P373: Daily aspirin use does not impact clinical outcomes in patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

P. Patel*, G. Gao, G. Gulotta, D.T. Rubin, S. Dalal, R.D. Cohen, A. Sakuraba, J. Pekow

University of Chicago, Chicago, USA